Search Clinical Trials
585,525 trials
ID
Status
Phase
Title
Sponsor
NCT07599293
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims DataBrigham and Women's HospitalActive Not Recruiting
NCT07599293Active Not Recruiting
—
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims DataBrigham and Women's Hospi...
NCT07598383
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic DermatitisJiangsu vcare pharmaceutical technology co., LTDNot Yet RecruitingPhase 2
NCT07598383Not Yet Recruiting
Phase 2
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical St...Jiangsu vcare pharmaceuti...
NCT07598318
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR MutationsSir Run Run Shaw HospitalNot Yet RecruitingPhase 2
NCT07598318Not Yet Recruiting
Phase 2
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Ca...Sir Run Run Shaw Hospital
NCT07599813
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic DermatitisApollo Therapeutics LtdRecruitingPhase 2
NCT07599813Recruiting
Phase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Sever...Apollo Therapeutics Ltd
NCT07599709
LONG PULSED ND:YAG LASER (1064 NM) VERSUS INTENSE PULSED LIGHT IN TREATMENT OF TRAUMATIC AND POST-SURGICAL ERYTHEMATOUS SCARSAlexandria UniversityCompletedNot Applicable
NCT07599709Completed
Not Applicable
LONG PULSED ND:YAG LASER (1064 NM) VERSUS INTENSE PULSED LIGHT IN TREATMENT OF T...Alexandria University
NCT07598786
Development and Strategic Research of Practical Applications in Sports NutritionNational Taiwan Sport UniversityNot Yet RecruitingNot Applicable
NCT07598786Not Yet Recruiting
Not Applicable
Development and Strategic Research of Practical Applications in Sports NutritionNational Taiwan Sport Uni...
NCT07599085
Early Feasibility Study to Assess the Safety and Effectiveness of the OnePoint Dialysis CannulaTM as a Single-Site Vascular Access Device for Hemodialysis ProceduresEvolve Medicus, Inc.Not Yet RecruitingNot Applicable
NCT07599085Not Yet Recruiting
Not Applicable
Early Feasibility Study to Assess the Safety and Effectiveness of the OnePoint D...Evolve Medicus, Inc.
NCT07599176
Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPhase 1
NCT07599176Recruiting
Phase 1
Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsNational Heart, Lung, and...
NCT07599332
Observational Study Exploring the Timing of Postnatal Neonate Weight MeasurementsEast Suffolk and North Essex NHS Foundation TrustRecruiting
NCT07599332Recruiting
—
Observational Study Exploring the Timing of Postnatal Neonate Weight Measurement...East Suffolk and North Es...
NCT07600528
A Exploratory Study of NatureU Sweet Dream on Sleep OutcomesOmniSolutions Laboratory Holdings LimitedCompletedNot Applicable
NCT07600528Completed
Not Applicable
A Exploratory Study of NatureU Sweet Dream on Sleep OutcomesOmniSolutions Laboratory...
NCT07599657
Surfactant Protein D Levels in GCF Before and After MINST in PeriodontitisCairo UniversityRecruitingNot Applicable
NCT07599657Recruiting
Not Applicable
Surfactant Protein D Levels in GCF Before and After MINST in PeriodontitisCairo University
NCT07598370
A Study of LY3439539 in Participants With Alzheimer's DiseaseEli Lilly and CompanyNot Yet RecruitingPhase 1
NCT07598370Not Yet Recruiting
Phase 1
A Study of LY3439539 in Participants With Alzheimer's DiseaseEli Lilly and Company
NCT07598084
Non-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Synthetic Contrast EnhancementPeking University People's HospitalNot Yet Recruiting
NCT07598084Not Yet Recruiting
—
Non-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Sy...Peking University People'...
NCT07598448
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainNovartis PharmaceuticalsNot Yet Recruiting
NCT07598448Not Yet Recruiting
—
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Thr...Novartis Pharmaceuticals
NCT07598006
Hypervirulent Amoxicillin-Susceptible Klebsiella Pneumoniae CC66, France, 2016-2023Centre Hospitalier Universitaire de NiceCompleted
NCT07598006Completed
—
Hypervirulent Amoxicillin-Susceptible Klebsiella Pneumoniae CC66, France, 2016-2...Centre Hospitalier Univer...
NCT07598396
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus NephritisHoffmann-La RocheRecruitingPhase 2
NCT07598396Recruiting
Phase 2
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythemato...Hoffmann-La Roche
NCT07598708
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of HypersomnolenceCentessa Pharmaceuticals (UK) LimitedNot Yet RecruitingPhase 2
NCT07598708Not Yet Recruiting
Phase 2
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the...Centessa Pharmaceuticals...
NCT07598721
Evaluation of Abridge Ambient AI Technology Regarding Provider Burnout and Patient Satisfaction With the Clinical EncounterUniversity of WashingtonCompletedNot Applicable
NCT07598721Completed
Not Applicable
Evaluation of Abridge Ambient AI Technology Regarding Provider Burnout and Patie...University of Washington
NCT07598279
Peripheral Vascular Disease as a Clinical Trigger for Opportunistic Lung Cancer Screening Referral: An Implementation StudyInternational Agency for Research on CancerNot Yet RecruitingNot Applicable
NCT07598279Not Yet Recruiting
Not Applicable
Peripheral Vascular Disease as a Clinical Trigger for Opportunistic Lung Cancer...International Agency for...
Result Breakdown
Not yet recruiting9 (45%)
Recruiting6 (30%)
Completed4 (20%)
Active, not recruiting1 (5%)
not_applicable7 (35%)
Not Specified6 (30%)
Phase 25 (25%)
Phase 12 (10%)